about
Treatment of Dermatological Conditions Associated with HIV/AIDS: The Scarcity of Guidance on a Global ScaleReport from the National Institute of Allergy and Infectious Diseases workshop on drug allergy.Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism-dependent haptenation and T-cell proliferation in vivoFactors associated with increased mortality in a predominantly HIV-infected population with Stevens Johnson syndrome and toxic epidermal necrolysisIncreased adverse drug reactions to antimicrobials and anticonvulsants in patients with HIV infection.Less common oral lesions associated with HIV infection: prevalence and classification.Fluconazole induced toxic epidermal necrolysis: a case report.Atypical cutaneous lymphoproliferative disorder in patients with HIV infection.Dermatological manifestations in HIV-infected patients at a tertiary care hospital in a tribal (Bastar) region of Chhattisgarh, India.Ivermectin induced Steven-Johnsons syndrome: case report.Diagnosis of allergic reactions to sulfonamides.Erythema multiforme caused by Treponema pallidum in a young patient with human immunodeficiency virus infectionCost-effectiveness analysis of diagnostic options for pneumocystis pneumonia (PCP)The urologist and the patient infected with human immunodeficiency virus or with acquired immunodeficiency syndrome.Association of neighborhood-level factors with hospitalization for community-associated methicillin-resistant Staphylococcus aureus, New York City, 2006: a multilevel observational study.Aciclovir desensitisation and rechallenge.Dermatological findings correlated with CD4 lymphocyte counts in a prospective 3 year study of 1161 patients with human immunodeficiency virus disease predominantly acquired through intravenous drug abuse.Patients with HIV infection and fever: a diagnostic approach.Oral lesions associated with nevirapine-related Stevens Johnson syndrome: A report of four casesDrug hypersensitivity in human immunodeficiency virus-infected patient: challenging diagnosis and management.Cutaneous manifestations of opportunistic infections in patients infected with human immunodeficiency virusSeborrhoeic dermatitis of the scalpTherapy of falciparum malaria in sub-saharan Africa: from molecule to policy.HIV-Antiretroviral Therapy Induced Liver, Gastrointestinal, and Pancreatic Injury.Cutaneous effects of highly active antiretroviral therapy in HIV-infected patients.Dermatology for the allergist.Mechanisms of drug-induced delayed-type hypersensitivity reactions in the skinEpidemiology of psoriasis. Review and the German perspective.Temporal trends in mucocutaneous findings among human immunodeficiency virus 1-infected children in a population-based cohortAssessment of safety of the major antimalarial drugs.Effect of polyI:C cotreatment on halothane-induced liver injury in miceStevens-Johnson syndrome: pathogenesis, diagnosis, and management.Pharmacogenetic information derived from analysis of HLA alleles.Clinical analysis of HIV/AIDS patients with drug eruption in Yunnan, China.HLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients.[Geriatric dermatoses in patients hospitalized in the Department of Dermatology in Bamako (Mali)].Severe drug eruptions revisited.Common skin conditions in children with HIV/AIDS.Cutaneous adverse drug reactions to anti-tuberculosis drugs: state of the art and into the future.The impact of human immunodeficiency virus-related diseases on pigmented skin types.
P2860
Q26744549-39D21D82-C941-4FD4-B153-A89CE46CF732Q26800964-C2608E54-7A54-4111-BAF5-2E6F934EF9E7Q28364889-26F22914-09E2-4E1A-8660-19C7E0E3911BQ28541785-7AE83C01-FDD0-4E05-B84A-0CACBC1D7495Q33254111-F2688701-D920-4E52-B965-19762DF27168Q33501554-5E5B39A7-B7B5-4CB8-B9CB-F15AA98BE7BCQ33580210-E147533A-4EF5-4C1C-A45C-3B1B102A56CFQ33587464-1937A4E4-224F-46EE-AE3E-83DF0B8C1A3CQ33595458-A38E6EE7-4018-4780-B8C9-D47A0FC4E2D3Q33651703-F7CD84D5-EA6B-472B-96A9-A83152168F32Q33874332-61D566E8-DDD5-4AA8-8DF2-649B96B34BE1Q33963517-F5604F27-7813-484C-85D6-CA173ECA3186Q33999209-A7355483-B680-4212-BDDD-939BAF9BD62FQ34419035-9B661715-5711-4E20-B92A-AD06EBD11130Q34584922-05B18844-6528-4717-B3AD-4C5182A949A3Q34713187-6202637C-457D-402D-87E7-7F14208C3B74Q34753805-C061DECB-57CE-4C8F-9D31-10C4ADA79949Q35014909-229D7E68-C29F-4AED-8D27-55EB0F42838BQ35075291-817DB836-21B2-4FC1-B56D-4647D5C6086BQ35094201-3F72B511-5F77-444C-B99C-EC9427A58BEEQ35535201-FA963D3D-DB07-4E15-B71B-B2FC2AE3641CQ35643158-A0704C91-9A8C-4547-8B05-161FF88DB67DQ35838600-8643644C-940F-4D40-B114-6A104E613ECFQ35852627-AF05DA3F-0C39-4434-A0C1-8F1A8802A03FQ36103159-D8103619-DE0D-4EEC-BB6E-00987705BA8FQ36370900-574DB2DE-505D-4734-BC34-29993480138EQ36440366-04284A27-7ED4-4D74-B81A-BB8B92DD11D2Q36481432-6C66C8FB-01B9-4144-B517-E8E430A12729Q36612142-8F477B1B-5CC5-4EC3-804A-27086CF071EFQ36945007-4203FCD7-5743-4097-A6AD-A495E6F8B845Q37085300-6EB47D8B-0C34-4F19-B4C9-F8FE6FBD88DAQ37091877-B2CE3949-E33A-4F0B-A4FC-3EC1F6FDC6E5Q37120841-540C0223-70CD-495E-A8C1-604B209FDF6EQ37379483-23619370-6C69-4EE0-A4F7-CF7F1C47B01EQ37414313-ED2CE5FB-6714-4AAE-86F4-1D0125EC5BEAQ37666670-9CEB3A11-E88D-4F2B-A037-85F64CD5CBA6Q37992545-32927AFC-4117-4891-80F7-0D64B78FA331Q37992671-2BF06418-15D7-4674-9E96-71147A4A4F7DQ38003494-BDD217DF-917F-4FEE-B1B7-E538305DD23CQ38149872-319345A8-0C5A-4678-99DF-CCDAE9F56E2C
P2860
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh-hant
name
Cutaneous disease and drug reactions in HIV infection.
@en
Cutaneous disease and drug reactions in HIV infection.
@nl
type
label
Cutaneous disease and drug reactions in HIV infection.
@en
Cutaneous disease and drug reactions in HIV infection.
@nl
prefLabel
Cutaneous disease and drug reactions in HIV infection.
@en
Cutaneous disease and drug reactions in HIV infection.
@nl
P2093
P1476
Cutaneous disease and drug reactions in HIV infection.
@en
P2093
P304
P356
10.1056/NEJM199306103282304
P407
P577
1993-06-01T00:00:00Z